We are live on ! Find out more
NXTC icon

NextCure
NXTC

26 hedge funds and large institutions have $23M invested in NextCure in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

8% more funds holding

Funds holding: 24 → 26 (+2)

6.8% more ownership

Funds ownership: 54.13% → 60.93% (+6.8%)

15% less capital invested

Capital invested by funds: $26.9M → $23M (-$3.97M)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
26
Holders Change
+2
Holders Change %
+8.33%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
OM
Opaleye Management
Massachusetts
+$1.72M
2
VA
Verdad Advisers
Massachusetts
+$525K
3
SCM
Squadron Capital Management
Illinois
+$342K
4
WP
Woodline Partners
California
+$336K
5
Renaissance Technologies
Renaissance Technologies
New York
+$329K

Top Sellers

1
EAM
Exome Asset Management
New York
-$605K
2
Millennium Management
Millennium Management
New York
-$185K
3
Marshall Wace
Marshall Wace
United Kingdom
-$160K
4
SCM
Sio Capital Management
New York
-$155K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$95.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Squadron Capital Management
Illinois
$2.83M +$342K +28,034 +12%
AAA
2
Affinity Asset Advisors
New York
$2.58M -$66.8K -5,468 -2%
IC
3
Ikarian Capital
Texas
$2.51M – – –
SI
4
Sofinnova Investments
California
$2.38M – – –
SCM
5
Silverarc Capital Management
Massachusetts
$1.88M – – –
VCM
6
Vanguard Capital Management
Pennsylvania
$1.69M +$1.96M +160,473 New
P
7
Pfizer
New York
$1.54M -$52.4K -4,292 -3%
OM
8
Opaleye Management
Massachusetts
$1.51M +$1.72M +141,181 New
AIC
9
AWM Investment Company
New York
$1.23M – – –
EAM
10
Exome Asset Management
New York
$1.22M -$605K -49,500 -30%
BFM
11
Boothbay Fund Management
New York
$744K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$647K +$329K +26,900 +80%
VA
13
Verdad Advisers
Massachusetts
$459K +$525K +42,955 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$327K +$96.9K +7,935 +34%
BlackRock
15
BlackRock
New York
$297K – – –
WP
16
Woodline Partners
California
$294K +$336K +27,498 New
CPA
17
Cardiff Park Advisors
California
$233K – – –
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$199K -$95.1K -7,783 -29%
VFT
19
Vanguard Fiduciary Trust
Pennsylvania
$168K +$196K +16,015 New
Citadel Advisors
20
Citadel Advisors
Florida
$161K +$187K +15,292 New
Barclays
21
Barclays
United Kingdom
$60.1K – – –
UBS Group
22
UBS Group
Switzerland
$3.61K – – –
Morgan Stanley
23
Morgan Stanley
New York
$705 – – –
JP Morgan Chase
24
JP Morgan Chase
New York
$587 – – –
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$342 – – –
1
2

NXTC Hedge Fund Activity: Q1 2026 in Review

26 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2026, worth a combined $23M — down 15% from $26.9M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NXTC positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $1.72M. The largest seller was Exome Asset Management, cutting an estimated $605K.

  • 26 institutional investors held NextCure (NXTC) as of Q1 2026, up from 24 in Q4 2025.
  • Funds reported $23M of NextCure stock for Q1 2026, down 15% quarter-over-quarter.
  • 7 funds opened new NextCure positions in Q1 2026 and 4 closed out, a net change of +3 holders.
  • The largest NextCure buyer in Q1 2026 was Opaleye Management, an estimated $1.72M added.
  • The largest NextCure seller in Q1 2026 was Exome Asset Management, an estimated $605K sold.

Based on aggregated 13F filings for Q1 2026.